Nuvectis Pharma (Nuvectis Pharma) Debt-to-EBITDA : 0.00 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Nuvectis Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Nuvectis Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Nuvectis Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Nuvectis Pharma's annualized EBITDA for the quarter that ended in Mar. 2024 was $-17.58 Mil. Nuvectis Pharma's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Nuvectis Pharma's Debt-to-EBITDA or its related term are showing as below:

NVCT's Debt-to-EBITDA is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.31
* Ranked among companies with meaningful Debt-to-EBITDA only.

Nuvectis Pharma Debt-to-EBITDA Historical Data

The historical data trend for Nuvectis Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvectis Pharma Debt-to-EBITDA Chart

Nuvectis Pharma Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

N/A

Nuvectis Pharma Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Nuvectis Pharma's Debt-to-EBITDA

For the Biotechnology subindustry, Nuvectis Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvectis Pharma's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvectis Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Nuvectis Pharma's Debt-to-EBITDA falls into.

Nuvectis Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Nuvectis Pharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-22.897
	=	0.00

Nuvectis Pharma's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-17.584
	=	0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Nuvectis Pharma (NAS:NVCT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Nuvectis Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Nuvectis Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvectis Pharma (Nuvectis Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvectis Pharma Inc (NAS:NVCT) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024

Website

https://www.nuvectis.com

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. Its pipeline products include NXP800, NXP900.

Executives

Ron Bentsur	director, officer: Chairman & CEO	750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Marlio Charles Mosseri	10 percent owner	27 RIPPLEVALE GROVE, LONDON X0 N1 1HS
Enrique Poradosu	officer: Chief Science and Business Off	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, FORT LEE NJ 07024
Shay Shemesh	officer: Chief Development Officer	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Michael J. Carson	officer: Vice President, Finance	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Kenneth Hoberman	director	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Oliviero James F Iii	director	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Uri Ben-or	officer: Int. Principal Financial Off.	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Matthew L. Kaplan	director	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024